Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
J Am Med Inform Assoc. 2012 Nov-Dec;19(6):1115-8. doi: 10.1136/amiajnl-2012-000960. Epub 2012 Aug 9.
Residual clinical samples represent a very appealing source of biomaterial for translational and clinical research. We describe the implementation of an opt-in biobank, with consent being obtained at the time of registration and the decision stored in our electronic health record, Epic. Information on that decision, along with laboratory data, is transferred to an application that signals to biobank staff whether a given sample can be kept for research. Investigators can search for samples using our i2b2 data warehouse. Patient participation has been overwhelmingly positive and much higher than anticipated. Over 86% of patients provided consent and almost 83% requested to be notified of any incidental research findings. In 6 months, we obtained decisions from over 18 000 patients and processed 8000 blood samples for storage in our research biobank. However, commercial electronic health records like Epic lack key functionality required by a registrar-based consent process, although workarounds exist.
剩余的临床样本是转化和临床研究非常有吸引力的生物材料来源。我们描述了一个选择加入型生物库的实施情况,在注册时获得同意,并将该决定存储在我们的电子健康记录 Epic 中。关于该决定的信息以及实验室数据被转移到一个应用程序中,该应用程序向生物库工作人员发出信号,指示给定的样本是否可以用于研究。研究人员可以使用我们的 i2b2 数据仓库搜索样本。患者的参与度非常高,远远超出预期。超过 86%的患者提供了同意,近 83%的患者要求被告知任何偶然的研究结果。在 6 个月内,我们从超过 18000 名患者那里获得了决定,并处理了 8000 份血液样本用于我们的研究生物库储存。然而,像 Epic 这样的商业电子健康记录缺乏基于登记员的同意过程所需的关键功能,尽管存在解决方法。